Inductive Bio key facts
as of Oct 2026- Developer of a machine learning platform designed to accelerate the compound optimization process.
- Inductive Bio is valued at approximately $80.0M as of Oct 2026, set at its early-stage round, May 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $29.4M across 2 recorded rounds; the latest was Early Stage VC ($25.1M) in Mar 2025.
- Notable investors include Andreessen Horowitz, Bessemer Venture Partners, Lux Capital, AlleyCorp, S32 — 16 tracked in total.
- Inductive Bio has filed 1 Form D with the SEC, most recently May 2025 ($25.1M sold to 10 investors).
- Status: Privately Held (backing).
Valued at $80.0M at its early-stage round, May 2025. Nothing has traded since.
- ·The complete investor list: 16 names
- ·Watch Inductive Bio: the Monday email on marks, rounds and moves
Inductive Bio funding rounds
2 roundsWho backs Inductive Bio
16+Membership and data by Private Market View
Inductive Bio valuation
Inductive Bio was valued at $80 million at its early-stage round in May 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Inductive Bio raised?
Inductive Bio has raised $29.4 million across 2 recorded rounds since 2023. The largest was a $4.3 million seed round in Dec 2023; the most recent was a $25.1 million early-stage round in Mar 2025.
Inductive Bio has filed 1 Form D with the SEC, most recently in May 2025 ($25.1 million sold to 10 investors).
Inductive Bio investors
16 investors are on record for Inductive Bio, including Andreessen Horowitz, Bessemer Venture Partners, Lux Capital and AlleyCorp. By type, the record holds 6 venture capital firms and 1 growth equity firm. The early-stage round in Mar 2025 drew 10 investors.
Comparable companies
Comparable decision/risk analysis names by valuation on PrivateMarketView: Anumana ($580 million), VideaHealth ($400 million) and Cellens ($19.4 million).
About Inductive Bio
Developer of a machine learning platform designed to accelerate the compound optimization process. The company's platform specializes in building datasets and machine learning (ML) models to map the drivers of small molecule absorption, distribution, metabolism, excretion, and toxicity (ADMET), enabling scientists to optimize initial compounds into leads and development candidates faster and with a better balance of properties which helps them develop new therapeutics.
- Industry
- Decision/Risk Analysis
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2021
- Website
- inductive.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.